Dr. Prashant Kesharwani is an Assistant Professor of Pharmaceutics at Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, India. His work focuses on translational nanomedicine, polymeric biomaterials, targeted drug delivery, nanoengineered drug delivery systems, and translational pharmaceutical research. He has contributed extensively to the scientific literature and has served as an editor of scholarly books. Dr. Kesharwani has received research funding from national agencies and has been recognized with awards and fellowships for his contributions to the field. His research interests include nanomedicine, targeted and stimuli-responsive drug delivery, polymeric nanocarriers, and related pharmaceutical applications. He is actively involved in scientific research, academic mentoring, and scholarly publishing. Dr. Chitra Thakur is an Assistant Professor-Research in the Department of Pathology at the Stony Brook Cancer Center, New York, USA. She is a cancer biologist and has expertise in molecular oncology, mouse models of human cancers, analyzing big data in translational research, toxicology, and epigenetics in human cancers. She is the recipient of several internationally acclaimed awards such as the “DFG German Excellence Initiative Award,”, “NIH-Big Data Training for Translational Omics Research” and “American Cancer Society IRG”. With more than 45 research articles published in mainstream scientific journals, she has contributed significantly towards the understanding of the molecular mechanisms in human cancers. She is engrossed in cancer research, teaching, and community outreach initiatives, hence fostering the scientific community and health care professionals engaged in cancer diagnosis, and treatment.

• SECTION 1 Overview of cancer, internal and external factors associated with cancer1. Overview of cancer: Mechanisms of carcinogenesis2. Tumor metabolism and micronutrients: New insights to target malignant tumors3. The role of one-carbon amino acids in tumor-immune metabolism: From oncogenesis to therapy4. Environmental causes of cancer5. Cancer stem cells—Challenges for cancer therapies6. Carving a therapeutic niche for metastatic cancer: Opportunities and challengesSECTION 2 Epigenetics and its importance in cancer therapies7. An overview of epigenetics and cancer8. Metabolic adaptation and epigenetic modulations: Unraveling tumor plasticity under variable tumor microenvironment9. Involvement of epigenetic modifications in cancer stem cells and chemoresistance10. Cancer biomarkers: Where genetics meets epigenetics11. Epigenetics approach in cancer treatment with focus on lung and breast cancer12. Dietary components as epigenetic modifiers and their roles in cancer preventionSECTION 3 Nanomedicine targeting epigenetic machinery in cancer therapy13. Harnessing plant-derived biosynthetic nanomaterials for epigenetic modulation in cancer therapy14. Nanotechnology-enhanced immunotherapy for cancer15. Nanoparticles in metastatic cancer treatment16. Amine-terminated dendrimers: A novel method for diagnose, control and treatment of cancer17. Nanomedicine and epigenome: Possible health risks, benefits, and future perspectives18. Smart cancer nanomedicine: Challenges and future opportunities

Select Guide Rating